Avalo Therapeutics, Inc. (AVTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$15.47−$0.2500 (−1.59%) on the dayAs of the close; data may be delayed.
AVTX price, last 12 months
Key stats
- Previous close
- $15.72
- Open
- $15.75
- Day range
- $15.00 – $15.81
- 52-week range
- $10.70 – $24.27
- Volume
- 1.4M
- Avg volume (20 days)
- 1.1M
- Market cap
- $829.7M
Performance
1W−6.6%
1M−24.7%
3M−15.0%
6M+10.9%
YTD−14.8%
1Y+33.4%
vs S&P 500, 1Y+16.6 pts
Technicals and fundamentals
About Avalo Therapeutics, Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $829.7M